You are here

  • Home
  • Archive
  • Volume 10, Issue 11
  • Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG

 

Online download statistics by month:

Online download statistics by month: November 2022 to March 2026

AbstractFullPdf
Nov 2022595916
Dec 2022605610227
Jan 202327127160
Feb 202313613738
Mar 202310210433
Apr 2023848439
May 2023898933
Jun 2023636314
Jul 2023969645
Aug 2023989840
Sep 2023666729
Oct 2023858518
Nov 2023717127
Dec 202311811848
Jan 20246465128
Feb 2024484827
Mar 2024575799
Apr 2024646346
May 2024747432
Jun 2024504934
Jul 2024646530
Aug 2024373616
Sep 2024717145
Oct 2024616126
Nov 2024949566
Dec 2024666731
Jan 2025717128
Feb 202510010016
Mar 2025898935
Apr 202511611647
May 2025949440
Jun 2025696915
Jul 2025220
Mar 2026110
Total323532451428